Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: Br J Haematol. 2022 Sep 6;200(1):35–44. doi: 10.1111/bjh.18441

Figure 3.

Figure 3.

Progression free survival for the entire cohort stratified by Deauville 5-point score (A), 75th percentile maximum standardized uptake value (B), 75th percentile total metabolic tumor volume (C), and 75th percentile total lesion glycolysis (D). Dashed line delineates median survival time. Median PFS for 5PS of 5 was 0.4 years (95% CI 0.3–2.4) and for 5PS of 4 was 4.6 years (95% CI 0.8-NA). Median PFS for high SUVmax was 0.3 years (95% CI 0.09–1.1) and for low SUVmax was 3.5 years (95% CI 0.8-NA). Median PFS for high TMTV was 0.3 years (95% CI 0.1-NA) and for low TMTV was 2.4 years (95% CI 0.7-NA). Median PFS for high TLG was 0.3 years (95% CI 0.1–0.9 years) and for low TLG was 3.5 years (95% CI 0.8-NA).